TrialClinical cancer research : an official journal of the American Association for Cancer Research2026

PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis.

Yushang Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.